Inhibrx Biosciences reported its third‑quarter 2025 financial results, showing revenue of $1.3 million—up from $100 thousand in the same period a year earlier—primarily driven by licensing‑fee income.
The company posted a net loss of $35.3 million, with operating expenses of $33.8 million. The loss is largely attributable to continued investment in research and development, a typical pattern for a clinical‑stage biopharmaceutical focused on multivalent antibody candidates.
Cash and cash equivalents stood at $153.1 million as of September 30, 2025, providing a 12‑month runway for ongoing clinical development. The balance is bolstered by a recent debt facility, supporting activity through the end of 2026.
The earnings highlight the first commercial traction from Inhibrx’s licensing strategy, suggesting a potential revenue stream that could offset future operating losses as the pipeline advances. The company remains reliant on external financing and is awaiting key clinical data from its ozekibart and INBRX‑106 programs.
Investors will closely monitor Inhibrx’s ability to convert pipeline progress into revenue and to extend its cash runway beyond the current 12‑month horizon. No analyst expectations or forward guidance were disclosed in the release.
The market reaction to the results is not reported in the available information.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.